Pamplona Capital Management Buys Majority Stake in Alvogen
LONDON and NEW YORK, April 2, 2014-- Pamplona Capital Management LLP "Pamplona" is pleased to announce that it has acquired a majority stake in Alvogen, one of the fastest growing generics companies in the pharmaceutical industry.
The stake was acquired from legacy shareholders through Pamplona's Private Equity Fund III. The value was not disclosed. Robert Wessman, the Founder and CEO of Alvogen and the existing management team, will continue to operate the business.
Domiciled in Luxembourg, Alvogen employs 2,000 people and currently operates in 34 markets across the US, Central and Eastern Europe and the Asia Pacific region, with manufacturing hubs in New Jersey, Romania, and South Korea.
Alvogen's focus on niche generic products in the United States is complemented by its branded generic and OTC businesses in Central and Eastern Europe and Asia Pacific. Alvogen has a deep product pipeline of more than 200 pharmaceutical projects in development and registration, including several potential first-to-file and first-to-market opportunities. The Company also has a biosimilar presence and recently launched the first biosimilar monoclonal antibody approved in Central and Eastern Europe, Inflectra™.
"We are delighted to be welcoming Pamplona as a partner in our business. Pamplona is completely aligned with our strategy to develop Alvogen's platform for future growth and will provide us with the additional financial capability to make strategic investments and selective acquisitions," said Robert Wessman, Chairman and Chief Executive Officer of Alvogen.
"Robert is one of the leading figures in the global generics industry and he and his team have built a first class business with excellent prospects for future growth. We are very excited about being able to work with the Alvogen team in building on this success," said Jeremy Gelber, Partner at Pamplona.
Jefferies and Perella Weinberg Partners acted as financial advisors to Pamplona, and Jefferies provided the sole financing commitment for the transaction. Legal advice was provided by Lowenstein Sandler LLP and Allen & Overy.
Alvogen is a multinational, privately owned pharmaceuticals company focused on developing, manufacturing and distributing generic, brand, over-the-counter brands (OTC) and biosimilar products. With more than 200 pharmaceutical projects in development and registration, the group's product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of: oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has commercial operations in over 30 countries across North America, Central and Eastern Europe, and Asia Pacific, and has over 2000 employees.
About Pamplona Capital Management
Pamplona Capital Management is a London and New York based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds and single manager hedge fund investments. Pamplona manages over $6.0 billion in assets for a variety of clients including public pension funds, international wealth managers, multinational corporations, family offices and funds of hedge funds. Pamplona is currently managing its third private equity fund, Pamplona Capital Partners III, LP, which was raised in 2011 and has committed capital of $2.7 billion. Pamplona invests long-term capital across the capital structure of its portfolio companies in both public and private market situations.
Temple Bar Advisory
Ed Orlebar/Tom Allison
Venture Capital Database